Species | Target name | Source | Bibliographic reference |
---|---|---|---|
Homo sapiens | 5-hydroxytryptamine (serotonin) receptor 2A, G protein-coupled | Starlite/ChEMBL | References |
Rattus norvegicus | Glutamate [NMDA] receptor subunit epsilon 3 | Starlite/ChEMBL | References |
Rattus norvegicus | Muscarinic acetylcholine receptor M3 | Starlite/ChEMBL | References |
Rattus norvegicus | Alpha-1a adrenergic receptor | Starlite/ChEMBL | References |
Homo sapiens | 5-hydroxytryptamine (serotonin) receptor 2B, G protein-coupled | References | |
Rattus norvegicus | Muscarinic acetylcholine receptor M2 | Starlite/ChEMBL | References |
Rattus norvegicus | Opioid receptor | Starlite/ChEMBL | References |
Rattus norvegicus | Alpha-1b adrenergic receptor | Starlite/ChEMBL | References |
Homo sapiens | sigma non-opioid intracellular receptor 1 | Starlite/ChEMBL | References |
Rattus norvegicus | Dopamine D2 receptor | Starlite/ChEMBL | References |
Homo sapiens | 5-hydroxytryptamine (serotonin) receptor 2C, G protein-coupled | References |
Species | Potential target | Raw | Global | Species |
---|---|---|---|---|
Echinococcus granulosus | hypothetical protein | 0.0859 | 0.5912 | 0.5912 |
Trypanosoma brucei | C-8 sterol isomerase, putative | 0.0662 | 0.4425 | 0.5 |
Leishmania major | C-8 sterol isomerase-like protein | 0.0662 | 0.4425 | 0.5 |
Brugia malayi | ERG2 and Sigma1 receptor like protein | 0.0662 | 0.4425 | 1 |
Mycobacterium leprae | Probable anthranilate phosphoribosyltransferase TrpD | 0.0395 | 0.2413 | 0.5 |
Mycobacterium ulcerans | thymidine phosphorylase | 0.1401 | 1 | 1 |
Loa Loa (eye worm) | hypothetical protein | 0.0526 | 0.3397 | 0.6867 |
Schistosoma mansoni | amine GPCR | 0.0226 | 0.1133 | 1 |
Trypanosoma cruzi | C-8 sterol isomerase, putative | 0.0662 | 0.4425 | 0.5 |
Mycobacterium tuberculosis | Probable thymidine phosphorylase DeoA (tdrpase) (pyrimidine phosphorylase) | 0.1401 | 1 | 1 |
Loa Loa (eye worm) | hypothetical protein | 0.0662 | 0.4425 | 1 |
Echinococcus multilocularis | thymidine phosphorylase | 0.1401 | 1 | 1 |
Loa Loa (eye worm) | hypothetical protein | 0.0526 | 0.3397 | 0.6867 |
Echinococcus multilocularis | conserved hypothetical protein | 0.0833 | 0.5717 | 0.5717 |
Activity type | Activity value | Assay description | Source | Reference |
---|---|---|---|---|
Ki (binding) | = 25 nM | Compound was tested for its binding affinity towards sigma 1 receptor using [3H]-(+)-pentazocine from guinea pig brain | ChEMBL. | 9572880 |
Ki (binding) | = 25 nM | Compound was tested for its binding affinity towards sigma 1 receptor using [3H]-(+)-pentazocine from guinea pig brain | ChEMBL. | 9572880 |
Ki (binding) | = 1700 nM | Binding affinity towards sigma 2 receptor using [3H]-DTG in the presence of 200 nM (+)-NANM from guinea pig brain | ChEMBL. | 9572880 |
Ki (binding) | > 10000 nM | Compound was tested for its binding affinity towards 5-hydroxytryptamine 2 receptor using [3H]-ketanserin from guinea pig frontal cortex | ChEMBL. | 9572880 |
Ki (binding) | > 10000 nM | Compound was tested for its binding affinity towards Dopamine receptor D2 using [3H]-spiperone from rat striatum | ChEMBL. | 9572880 |
Ki (binding) | > 10000 nM | Compound was tested for its binding affinity towards Alpha-1A adrenergic receptor using [3H]-prazosin from rat submaxillary gland | ChEMBL. | 9572880 |
Ki (binding) | > 10000 nM | Compound was tested for its binding affinity towards Alpha-1B adrenergic receptor using [3H]-prazosin from rat liver | ChEMBL. | 9572880 |
Ki (binding) | > 10000 nM | Compound was tested for its binding affinity towards Muscarinic acetylcholine receptor M2 using [3H]-NMS from rat heart | ChEMBL. | 9572880 |
Ki (binding) | > 10000 nM | Compound was tested for its binding affinity towards Muscarinic acetylcholine receptor M3 using [3H]-NMS from rat submaxillary gland | ChEMBL. | 9572880 |
Ki (binding) | > 10000 nM | Compound was tested for its binding affinity towards Opioid receptors using [3H]-naloxone from rat whole brain | ChEMBL. | 9572880 |
Ki (binding) | > 10000 nM | Compound was tested for its binding affinity towards PCP receptor using [3H]-(+)-NANM in the presence of 5 microM haloperidol from rat brain | ChEMBL. | 9572880 |
Ki (binding) | > 10000 nM | Compound was tested for its binding affinity towards 5-hydroxytryptamine 2 receptor using [3H]-ketanserin from guinea pig frontal cortex | ChEMBL. | 9572880 |
Ki (binding) | > 10000 nM | Compound was tested for its binding affinity towards Dopamine receptor D2 using [3H]-spiperone from rat striatum | ChEMBL. | 9572880 |
Ki (binding) | > 10000 nM | Compound was tested for its binding affinity towards Alpha-1A adrenergic receptor using [3H]-prazosin from rat submaxillary gland | ChEMBL. | 9572880 |
Ki (binding) | > 10000 nM | Compound was tested for its binding affinity towards Alpha-1B adrenergic receptor using [3H]-prazosin from rat liver | ChEMBL. | 9572880 |
Ki (binding) | > 10000 nM | Compound was tested for its binding affinity towards Muscarinic acetylcholine receptor M2 using [3H]-NMS from rat heart | ChEMBL. | 9572880 |
Ki (binding) | > 10000 nM | Compound was tested for its binding affinity towards Muscarinic acetylcholine receptor M3 using [3H]-NMS from rat submaxillary gland | ChEMBL. | 9572880 |
Ki (binding) | > 10000 nM | Compound was tested for its binding affinity towards Opioid receptors using [3H]-naloxone from rat whole brain | ChEMBL. | 9572880 |
Ki (binding) | > 10000 nM | Compound was tested for its binding affinity towards PCP receptor using [3H]-(+)-NANM in the presence of 5 microM haloperidol from rat brain | ChEMBL. | 9572880 |
Selectivity (binding) | = 68 | Selectivity for sigma 2 receptor and sigma 1 receptor from guinea pig brain was evaluated | ChEMBL. | 9572880 |
Selectivity (binding) | = 68 | Selectivity for sigma 2 receptor and sigma 1 receptor from guinea pig brain was evaluated | ChEMBL. | 9572880 |
Many chemical entities in TDR Targets come from high-throughput screenings with whole cells or tissue samples, and not all assayed compounds have been tested against a single a single target protein, probably because they get ruled out during screening process. Even if these compounds may have not been of interest in the original screening, they may come as interesting leads for other screening assays. Furthermore, we may be able to propose drug-target associations using chemical similarities and network patterns.
1 literature reference was collected for this gene.